Dr. Ali W. Bseiso
Claim this profileMarshfield Medical Center-Marshfield
Studies Leukemia
Studies Myeloid Leukemia
7 reported clinical trials
26 drugs studied
Area of expertise
1Leukemia
BCR-ABL1 positive
t(8;21) negative
inv(16) negative
2Myeloid Leukemia
t(8;21) negative
inv(16) negative
t(16;16) negative
Affiliated Hospitals
Clinical Trials Ali W. Bseiso is currently running
Pembrolizumab + TKI
for Chronic Myeloid Leukemia
This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic myeloid leukemia.
Recruiting1 award Phase 2
Blinatumomab + Chemotherapy
for Leukemia
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
Recruiting2 awards Phase 310 criteria
More about Ali W. Bseiso
Clinical Trial Related5 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Ali W. Bseiso has experience with
- Lenalidomide
- Dexamethasone
- Cytarabine
- Dasatinib
- Blinatumomab
- Gilteritinib
Breakdown of trials Ali W. Bseiso has run
Leukemia
Myeloid Leukemia
Chronic Myeloid Leukemia
Lymphoblastic Leukemia-Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ali W. Bseiso specialize in?
Ali W. Bseiso focuses on Leukemia and Myeloid Leukemia. In particular, much of their work with Leukemia has involved BCR-ABL1 positive patients, or patients who are t(8;21) negative.
Is Ali W. Bseiso currently recruiting for clinical trials?
Yes, Ali W. Bseiso is currently recruiting for 5 clinical trials in Marshfield Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Ali W. Bseiso has studied deeply?
Yes, Ali W. Bseiso has studied treatments such as Lenalidomide, Dexamethasone, Cytarabine.
What is the best way to schedule an appointment with Ali W. Bseiso?
Apply for one of the trials that Ali W. Bseiso is conducting.
What is the office address of Ali W. Bseiso?
The office of Ali W. Bseiso is located at: Marshfield Medical Center-Marshfield, Marshfield, Wisconsin 54449 United States. This is the address for their practice at the Marshfield Medical Center-Marshfield.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.